Better Therapeutics Ownership
Better Therapeutics holds a total of 54.52 Million outstanding shares. Better Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in otc stocks such as Better Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Better Therapeutics, and when they decide to sell, the otc stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Better |
Better OTC Stock Ownership Analysis
About 53.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.1. Better Therapeutics had not issued any dividends in recent years. Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California. Better Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.The quote for Better Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on Better Therapeutics please contact Frank Karbe at 415 887 2311 or go to https://www.bettertx.com.Better Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Better Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Better Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Better Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Perry David P over a year ago Acquisition by Perry David P of 839895 shares of Better Therapeutics subject to Rule 16b-3 | ||
Perry David P over a year ago Acquisition by Perry David P of 1471453 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over a year ago Acquisition by Miller Leslie A of 3587 shares of Better Therapeutics subject to Rule 16b-3 | ||
Miller Leslie A over a year ago Better Therapeutics exotic insider transaction detected | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 137005 shares of Better Therapeutics | ||
Lavizzomourey Risa J over a year ago Acquisition by Lavizzomourey Risa J of 15000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Mark Heinen over a year ago Acquisition by Mark Heinen of 54000 shares of Better Therapeutics subject to Rule 16b-3 | ||
Frank Karbe over a year ago Purchase by Frank Karbe of 242424 shares of Better Therapeutics |
Better Therapeutics Outstanding Bonds
Better Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Better Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Better bonds can be classified according to their maturity, which is the date when Better Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |